TELA Bio, Inc. (NASDAQ: TELA) has announced the European launch of its OviTex Inguinal Reinforced Tissue Matrix, the first ...

This milestone follows the successful U.S. launch of OviTex Inguinal in 2024, where it has achieved over $1 million in sales in its first year and has seen growing adoption by surgeons seeking a ...